StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies
Phase 2
Withdrawn
- Conditions
- MyelodysplasiaAcute Lymphocytic LeukemiaChronic Myelogenous LeukemiaAcute Myeloid Leukemia
- Interventions
- Biological: Unmanipulated UCBBiological: SR-1 UCB
- First Posted Date
- 2016-05-09
- Last Posted Date
- 2017-12-05
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Registration Number
- NCT02765997
- Locations
- 🇺🇸
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Phase 2
Active, not recruiting
- Conditions
- Myelodysplastic SyndromeMultiple MyelomaLymphoplasmacytic LymphomaMarginal Zone B-cell LymphomaProlymphocytic LeukemiaMRD Positive LeukemiaRelapsed T-Cell LymphomaAcute Myeloid LeukemiaAcute Lymphoblastic Leukemia/LymphomaBurkitt's Lymphoma
- Interventions
- Radiation: TBIBiological: Umbilical cord blood cell infusionBiological: ATG
- First Posted Date
- 2016-03-30
- Last Posted Date
- 2023-02-24
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 16
- Registration Number
- NCT02722668
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Study of Cellutome System for Treatment of Individual Lesions in EB Pts
Not Applicable
Completed
- Conditions
- Epidermolysis Bullosa
- Interventions
- Device: Cellutome Epidermal Harvesting System
- First Posted Date
- 2016-02-02
- Last Posted Date
- 2024-04-09
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 34
- Registration Number
- NCT02670837
- Locations
- 🇺🇸
University of Minnesota Masonic Cancer Center and Medical Center, Minneapolis, Minnesota, United States
Exemestane in Post-Menopausal Women With NSCLC
- First Posted Date
- 2016-01-28
- Last Posted Date
- 2023-05-31
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 6
- Registration Number
- NCT02666105
- Locations
- 🇺🇸
Essentia Health Hibbing, Hibbing, Minnesota, United States
🇺🇸Mayo Clinic Health System, Mankato, Minnesota, United States
🇺🇸Essentia Health Park Rapids, Park Rapids, Minnesota, United States
Allo HSCT Using RIC for Hematological Diseases
Phase 2
Completed
- Conditions
- Chronic Myelogenous LeukemiaLymphoplasmacytic LymphomaMantle-Cell LymphomaLymphoblastic LymphomaAcute Myelogenous LeukemiaChronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaBurkitt's LymphomaHematological DiseasesB-Cell Lymphoma
- Interventions
- Radiation: TBIBiological: Peripheral Blood Stem CellsBiological: Related or Unrelated Bone Marrow Cells
- First Posted Date
- 2016-01-21
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 156
- Registration Number
- NCT02661035
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
Phase 2
Recruiting
- Conditions
- Neuroblastoma
- Interventions
- Biological: Autologous Stem Cell InfusionBiological: Granulocyte colony stimulating factor
- First Posted Date
- 2015-11-16
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 12
- Registration Number
- NCT02605421
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs
Phase 2
Completed
- Conditions
- Epidermolysis Bullosa
- Interventions
- Radiation: Total Body IrradiationProcedure: Bone marrow infusionBiological: Donor mesenchymal stem cell infusions
- First Posted Date
- 2015-10-21
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 17
- Registration Number
- NCT02582775
- Locations
- 🇺🇸
University of Minnesota Masonic Cancer Center and Medical Center, Minneapolis, Minnesota, United States
Study of Pregnyl as Adjunct Therapy for High-Risk or Refractory Acute GVHD
- First Posted Date
- 2015-08-17
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 53
- Registration Number
- NCT02525029
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Investigation of Kava Effects on NNK Metabolism
Not Applicable
Completed
- Conditions
- Tobacco Smoking
- Interventions
- Dietary Supplement: Kava
- First Posted Date
- 2015-07-16
- Last Posted Date
- 2018-04-04
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 24
- Registration Number
- NCT02500472
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
MT2014-14 IT-MSC for Advanced Cerebral Adrenoleukodystrophy (cALD)
Phase 1
Withdrawn
- Conditions
- Cerebral Adrenoleukodystrophy
- Interventions
- Biological: Mesenchymal Stem Cells
- First Posted Date
- 2015-04-07
- Last Posted Date
- 2017-12-02
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Registration Number
- NCT02410239
© Copyright 2025. All Rights Reserved by MedPath